Introduction and Objectives: To our knowledge, only a few studies assessed continuous glucose monitoring (CGM) metrics in total pancreatectomy (TP) without islet autotransplantation during hospitalization.
Methods: We completed blinded CGM (Dexcom G6 Pro) studies in 28 subjects who had TP at Mayo Clinic, Rochester in a non-ICU setting and compared 2 cohorts (CGM data < 30 days of TP vs. ≥ 30 days of TP). CGM glucose metrics were calculated as per ADA guidelines for hospitalized patients with diabetes mellitus (DM). CGM values were compared with point-of-care -testing glucose within 5 minutes.
Results: Baseline characteristics were 50% F, age 59.5 ± 8.2 yrs, BMI 26.7 ± 3.4 kg/m2, preexisting type 2 DM (Y/N=8/20) with mean duration of DM 7.9 ± 8.8 yrs, malignant/benign pancreatic tumor 25/3 and CGM data of 4.6 ± 3.2 days. Time in target range (140-180 mg/dL) was between 13-27% and time above range was ≥48 % in both cohorts. Time <70 mg/dL was significantly higher in cohort 2 vs. cohort 1 (p=0.03). Overall, mean absolute relative difference (MARD) was 17.2% (± 4.9), median ARD was 19.4% and number of readings meeting % 20/20, was 68% with least accuracy on day 1. There was no device related adverse event.
Conclusion: Hospitalized TP patients spend more time above and below target range than within the target range demonstrating unmet needs of better glucose monitoring and better glycemic control.
S. Rizvi: None. A. Banerjee: None. R. Kaur: None. S. Gupta: None. C. Reid: None. D. Desjardins: None. M.L. Kendrick: None. M. Truty: None. Y.C. Kudva: Research Support; Dexcom, Inc. Other Relationship; Tandem Diabetes Care, Inc., Medtronic.
